Details for Patent: 9,243,245
✉ Email this page to a colleague
Which drugs does patent 9,243,245 protect, and when does it expire?
Patent 9,243,245 protects EXONDYS 51 and is included in one NDA.
This patent has seventy-four patent family members in seventeen countries.
Summary for Patent: 9,243,245
| Title: | Means and methods for counteracting muscle disorders |
| Abstract: | The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival. |
| Inventor(s): | De Kimpe; Josephus Johannes (Utrecht, NL), Platenburg; Gerard Johannes (Voorschoten, NL), Van Deutekom; Judith Christina Theodora (Dordrecht, NL), Aartsma-Rus; Annemieke (Hoofddorp, NL), Van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL) |
| Assignee: | Academisch Ziekenhuis Leiden (Leiden, NL) BioMarin Technologies B.V. (Leiden, NL) |
| Application Number: | 12/767,702 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Device; |
Drugs Protected by US Patent 9,243,245
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | ⤷ Try a Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | ⤷ Try a Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | ⤷ Try a Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,243,245
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 07119351 | Oct 26, 2007 | |
International Family Members for US Patent 9,243,245
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008317566 | ⤷ Try a Trial | |||
| Australia | 2009310557 | ⤷ Try a Trial | |||
| Australia | 2009310558 | ⤷ Try a Trial | |||
| Canada | 2704049 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
